PAM-VT 2研究:室速消融后晚期钆增强心脏磁共振评估瘢痕演变与消融病灶
前瞻性纳入51例结构性心脏病患者,首次基质室速消融后行系列LGE-CMR。消融后核心瘢痕质量增加并稳定,边界区和传导通道显著减少;CMR-1(3-6个月)传导通道≥2条与VT复发率75.6% vs 19.5%相关(HR 4.1,95%CI 2.4-12.1,P=0.012)。
要点
- 消融后3-6个月LGE-CMR传导通道≥2条与VT复发风险升高相关(HR 4.1,95%CI 2.4-12.1,P=0.012)。
- 消融后核心瘢痕质量增加并稳定,边界区和传导通道持续减少。
- VT消融与左室逆重构相关,CMR-2左室容积较基线显著减小。
核心结论
- 消融后LGE-CMR显示瘢痕特征持久改变,早期(3-6个月)评估与长期VT复发强相关。
- 瘢痕异质性和传导通道减少持续存在,支持LGE-CMR用于评估消融成功。
- VT消融与有利的左室逆重构相关,提示心律失常控制之外的潜在获益。
研究设计与样本
- 前瞻性研究,纳入51例首次接受基质室速消融患者(平均年龄65.2±9.8岁,男性95.8%,缺血性心脏病83%,左室射血分数34.5±10.4%)。
- 消融前及消融后3-6个月(CMR-1)、18-24个月(CMR-2)行LGE-CMR,分析核心瘢痕、边界区和传导通道。
- 监测VT复发,采用Cox比例风险模型评估复发相关因素,Kaplan-Meier曲线展示无VT生存。
主要发现
- 核心瘢痕质量从基线12.2±1.5 g增至CMR-1 19.8±1.6 g(P<0.01),CMR-2保持稳定。
- 边界区从基线25.3±1.8 g降至CMR-1 20.8±2.0 g和CMR-2 16.7±2.1 g(P<0.01)。
- 传导通道从基线均值2.4±0.2/中位2(IQR 1-3)降至CMR-1均值1.4±0.2/中位1(IQR 0-1)和CMR-2均值1.6±1.0/中位1(IQR 0-1)(P<0.001)。
- 中位随访3.1年,VT复发率29.4%;CMR-1传导通道≥2条者复发率75.6% vs 19.5%(HR 4.1,95%CI 2.4-12.1,P=0.012)。
- CMR-2左室容积131.8±8.6 mL,较CMR-1 156.7±8.1 mL和基线160.8±7.6 mL显著减小(P<0.01)。
关键数值与推荐
- CMR-1(消融后3-6个月)传导通道≥2条与VT复发风险升高相关(HR 4.1,95%CI 2.4-12.1,P=0.012)。
- CMR-1传导通道数量及其相对基线减少程度与VT复发相关。
临床怎么用
- 室速消融后3-6个月行LGE-CMR评估传导通道,可识别高复发风险患者。
- 传导通道≥2条者可能需强化随访或个体化抗心律失常管理。
局限性
- 样本量较小(51例),单中心前瞻性研究。
- 男性占比高(95.8%),缺血性心脏病为主(83%),结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) is useful for identifying ventricular tachycardia (VT) substrate in patients with structural heart disease. While preprocedural LGE-CMR is widely used for planning, the role of postprocedural LGE-CMR in evaluating VT ablation success and long-term scar evolution has been less explored. This study aimed to prospectively and systematically assess the long-term evolution of scar and ablation lesions using serial postablation LGE-CMR with long-term follow-up. METHODS: This prospective study included 51 patients (mean age, 65.2±9.8 years; men, 95.8%; ischemic heart disease, 83%; left ventricular ejection fraction, 34.5±10.4%) undergoing their first substrate-based VT ablation between March 2019 and July 2020. Preprocedural LGE-CMR and 2 postprocedural scans at 3 to 6 months (CMR-1) and 18 to 24 months (CMR-2) were performed. Scar characteristics, including core scar, border zone, and conducting channels, were analyzed. VT recurrence was monitored, and factors associated with recurrence were evaluated using a Cox proportional hazards model. A Kaplan-Meier curve was used to represent the VT-free survival function. RESULTS: Core scar mass increased significantly from baseline to CMR-1 (12.2±1.5 to 19.8±1.6 g, P<0.01) and remained stable at CMR-2. In contrast, the border zone decreased significantly over time (pre, 25.3±1.8 g; CMR-1, 20.8±2.0 g; CMR-2, 16.7±2.1 g; P<0.01). A significant decrease in conducting channels was noted after ablation and persisted at CMR-2 (pre, mean 2.4±0.2/median 2 [interquartile range, 1-3]; CMR-1, mean 1.4±0.2/median 1 [interquartile range, 0-1]; CMR-2, mean 1.6±1.0/median 1 [interquartile range, 0-1]; P<0.001). VT recurrence occurred in 29.4% of patients during a median follow-up of 3.1 years. The number of conducting channels at CMR-1 and their relative reduction from baseline were related to VT recurrence. The persistence of 2 or more conducting channels at CMR-1 was associated with a higher recurrence rate: 75.6 versus 19.5% (hazard ratio [HR]; 4.1; 95% CI, 2.4-12.1; P=0.012). Evidence of favorable left ventricular remodeling was observed, with a significant reduction in left ventricular volume at CMR-2 (131.8±8.6 mL; CMR-1, 156.7±8.1 mL and 160.8±7.6 mL at baseline <0.01). CONCLUSIONS: Postablation LGE-CMR reveals durable changes in scar characteristics, with early scar evaluation at 3 to 6 months strongly associated with long-term VT recurrence. The reduction in scar heterogeneity and conducting channels is sustained over time, underscoring the usefulness of LGE-CMR for assessing ablation success. Additionally, VT ablation appeared to be associated with favorable reverse remodeling, highlighting potential benefits beyond arrhythmia control. These findings support the use of LGE-CMR for personalized management following VT ablation.
引用
- Roca-Luque I, Garre P, Vázquez-Calvo S, et al. PAM-VT 2 Study: Long-Term Scar Evolution and Ablation Lesion Assessment by Late Gadolinium Enhancement Cardiac Magnetic Resonance After Ventricular Tachycardia Ablation. Circulation. 2026. PMID: 41766535. doi:10.1161/CIRCULATIONAHA.125.074748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。